Literature DB >> 17425416

Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously.

Silvia V Nates1, Laura C Martinez, Patricia A Barril, Leonardo J Ferreyra, Miguel O Giordano, Gisela Masachessi, Maria Beatriz Isa.   

Abstract

The persistence of poliovirus-neutralizing antibodies was investigated in 297 individuals residing in Argentina who had completed the vaccination cycle with four or five oral polio vaccine (OPV) doses 1 mo to 19 yr before this study. Seropositivity for the three polio types in individuals who had received four OPV doses remained high and stable, showing rates not less than 94.6, 98.2, and 91.1% for types 1, 2, and 3, respectively, for a period of at least 6 yr. Almost identical rates were found in children who completed a vaccination schedule of five OPV doses 1 to 2 yr earlier. However, humoral immunity to poliovirus types 3 and 1 declined significantly 9 and 17 yr, respectively, after the booster dose had been administered; in contrast, type 2 immunity remained fairly stable during the 19-yr study period. Overall, geometric mean titer values for poliovirus types 1 and 2 were higher than those for poliovirus type 3. This is likely a result of low initial poliovirus type 3 antibody titers that eventually fell below the limits of detection at later time points. The results indicate that although antibody titers primed by OPV decline over time, they are remarkably long-lived, immunity to poliovirus types 1 and 2 being more prevalent than that against type 3 at late intervals postvaccination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425416     DOI: 10.1089/vim.2006.0071

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  8 in total

1.  Successes and shortcomings of polio eradication: a transmission modeling analysis.

Authors:  Bryan T Mayer; Joseph N S Eisenberg; Christopher J Henry; M Gabriela M Gomes; Edward L Ionides; James S Koopman
Journal:  Am J Epidemiol       Date:  2013-04-16       Impact factor: 4.897

2.  Seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China.

Authors:  HaiBo Wang; Hui Cui; ZhenGrong Ding; Pian Ba; ShuangLi Zhu; Ning Wen; LiXin Hao; Jing Ning; Jie Zhang; De Yang; WenBo Xu; Yong Zhang; ChunXiang Fan; WenZhou Yu; XiaoFeng Liang; HuiMing Luo
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

3.  A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people.

Authors:  Hye-Jin Kim; Seoyeon Hwang; Somin Lee; Yunhyung Kwon; Kwangsook Park; Young Joon Park; Geun-Ryang Bae; Sang Won Lee; Yong-Seok Jeong; Ji-Yeon Hyeon
Journal:  BMC Infect Dis       Date:  2015-03-28       Impact factor: 3.090

4.  Quantifying the impact of expanded age group campaigns for polio eradication.

Authors:  Bradley G Wagner; Matthew R Behrend; Daniel J Klein; Alexander M Upfill-Brown; Philip A Eckhoff; Hao Hu
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

5.  OPV-like poliovirus type 1 detection in patients with severe acute respiratory syndrome.

Authors:  H Shen; B Bai; J Hou; Y Sun; Y Hu; Q Duan; R Gao; H Zhu; W Kong; D Xu; J Zhao; H Wang; P Mao
Journal:  Infection       Date:  2012-02-28       Impact factor: 3.553

6.  Cross-Reactive Antibody Responses against Nonpoliovirus Enteroviruses.

Authors:  Amy B Rosenfeld; Edmund Qian Long Shen; Michaela Melendez; Nischay Mishra; W Ian Lipkin; Vincent R Racaniello
Journal:  mBio       Date:  2022-01-18       Impact factor: 7.786

7.  Sero-survey of polio antibodies during wild poliovirus outbreak in southern Xinjiang Uygur Autonomous Region, China.

Authors:  Hai-Bo Wang; Shuang-Li Zhu; Jing-Shan Zheng; Ai-Li Gou; Hui Cui; Yong Zhang; Gui-Jun Ning; Chun-Xiang Fan; Yuan-Sheng Chen; Ke-Li Li; Ping Yuan; Chao Ma; Jing Ma; Hui Zheng; Xin-Chun Fan; Xin-Lan Li; Hai-Shu Tang; Xiao-Lei Li; Fan Zhang; Dong-Mei Yan; Dong-Yan Wang; Zhi-Qiang Cui; Li-Ping Ren; Hui Zhu; Hui-Ling Wang; Xiao-Hong Jiang; Hong-Qiu An; Yang Liu; Jing Li; Wen-Bo Xu; Ning Wen; Ai-Qiang Xu; Hui-Ming Luo
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

8.  Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

Authors:  Siddhartha Kumar Bhaumik; Raveendra R Kulkarni; William C Weldon; Eduardo L V Silveira; Hasan Ahmed; Sivaram Gunisetty; Anmol Chandele; Rustom Antia; Harish Verma; Roland Sutter; Mark A Pallansch; M Steven Oberste; Francois Villinger; Walter Orenstein; Kaja Murali-Krishna
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.